Our Solutions

Complimentary Webinar — Regulatory Submissions in Canada vs. the U.S

This webinar provides an overview of requirements for gaining approval to conduct a first-in-human (FIH) clinical trial via Health Canada’s Clinical Trial Authorization (CTA) process and the U.S. FDA’s Investigational New Drug (IND) submission process.

Watch Altasciences’ Paul Sidney, Senior Director, Compliance and Regulatory Affairs, and Dr. Joe Francisco, Chief Toxicologist, as they provide insight as to how and why the conduct of FIH clinical trials in Canada may, in some cases, provide a more expedient method to gain human clinical safety data.